Grace Therapeutics, Inc. Form 4 Filing

Opaleye Management Inc., a 10% owner of Grace Therapeutics, Inc., reported the acquisition of 9,771 shares of common stock on September 21, 2026, at a price of $2.10 per share. This transaction increased their holdings to 2,850,000 shares. Subsequently, on September 23, 2026, Opaleye Management Inc. acquired an additional 5,318 shares at the same price of $2.10 per share, bringing their total shares to 2,855,318. These transactions were made through Opaleye, L.P., with Opaleye Management Inc. acting as the investment manager. The filing clarifies that Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.